Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer

• Published in: Cancers 2021-12, Vol.13 (24), p.6314
• Main Authors: Mayayo-Peralta, Isabel, Faggion, Beatrice, Hoekman, Liesbeth, Morris, Ben, Lieftink, Cor, Goldsbrough, Isabella, Buluwela, Lakjaya, Siefert, Joseph C, Post, Harm, Altelaar, Maarten, Beijersbergen, Roderick, Ali, Simak, Zwart, Wilbert, Prekovic, Stefan
• Format: Article
• Language: English
• Subjects: Antibodies; Antitumor agents; Breast cancer; Cancer therapies; Chemoresistance; Chemotherapy; Cloning; CRISPR; Cyclin-dependent kinase 4; Drug tolerance; Endocrine therapy; Epidermal growth factor receptors; ESR1 protein; Estrogen receptors; Gene expression; Kinases; Ligands; Membranes; Metastases; Metastasis; Mutants; Mutation; Phosphatase; Potassium; Proteins; Senescence; Signal transduction; Targeted cancer therapy; Tumors; Viability
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13246314

While endocrine therapy is highly effective for the treatment of oestrogen receptor-α (ERα)-positive breast cancer, a significant number of patients will eventually experience disease progression and develop treatment-resistant, metastatic cancer. The majority of resistant tumours remain dependent on ERα-action, with activating gene mutations occurring in 15-40% of advanced cancers. Therefore, there is an urgent need to discover novel effective therapies that can eradicate cancer cells with aberrant ERα and to understand the cellular response underlying their action. Here, we evaluate the response of MCF7-derived, CRISPR-Cas9-generated cell lines expressing mutant ERα (Y537S) to a large number of drugs. We report sensitivity to numerous clinically approved inhibitors, including CDK4/6 inhibitor ribociclib, which is a standard-of-care therapy in the treatment of metastatic ERα-positive breast cancer and currently under evaluation in the neoadjuvant setting. Ribociclib treatment induces senescence in both wildtype and mutant ERα breast cancer models and leads to a broad-range drug tolerance. Strikingly, viability of cells undergoing ribociclib-induced cellular senescence is maintained via engagement of EGFR signalling, which may be therapeutically exploited in both wildtype and mutant ERα-positive breast cancer. Our study highlights a wide-spread reduction in sensitivity to anti-cancer drugs accompanied with an acquired vulnerability to EGFR inhibitors following CDK4/6 inhibitor treatment.